KR102276022B1 - 돌연변이체 idh1 및 idh2 억제제로서의 7-페닐에틸아미노-4h-피리미도[4,5-d][1,3]옥사진-2-온 화합물 - Google Patents

돌연변이체 idh1 및 idh2 억제제로서의 7-페닐에틸아미노-4h-피리미도[4,5-d][1,3]옥사진-2-온 화합물 Download PDF

Info

Publication number
KR102276022B1
KR102276022B1 KR1020197016855A KR20197016855A KR102276022B1 KR 102276022 B1 KR102276022 B1 KR 102276022B1 KR 1020197016855 A KR1020197016855 A KR 1020197016855A KR 20197016855 A KR20197016855 A KR 20197016855A KR 102276022 B1 KR102276022 B1 KR 102276022B1
Authority
KR
South Korea
Prior art keywords
ethyl
compound
phenyl
oxazin
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197016855A
Other languages
English (en)
Korean (ko)
Other versions
KR20190077539A (ko
Inventor
레나토 알레한드로 바우어
서지 루이즈 불레
티모시 폴 버크홀더
레이몬드 길모어
패트릭 제임스 한
조란 란코빅
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20190077539A publication Critical patent/KR20190077539A/ko
Application granted granted Critical
Publication of KR102276022B1 publication Critical patent/KR102276022B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020197016855A 2016-12-16 2017-12-08 돌연변이체 idh1 및 idh2 억제제로서의 7-페닐에틸아미노-4h-피리미도[4,5-d][1,3]옥사진-2-온 화합물 Active KR102276022B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662435283P 2016-12-16 2016-12-16
US62/435,283 2016-12-16
PCT/US2017/065246 WO2018111707A1 (en) 2016-12-16 2017-12-08 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors

Publications (2)

Publication Number Publication Date
KR20190077539A KR20190077539A (ko) 2019-07-03
KR102276022B1 true KR102276022B1 (ko) 2021-07-13

Family

ID=60888651

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197016855A Active KR102276022B1 (ko) 2016-12-16 2017-12-08 돌연변이체 idh1 및 idh2 억제제로서의 7-페닐에틸아미노-4h-피리미도[4,5-d][1,3]옥사진-2-온 화합물

Country Status (37)

Country Link
US (3) US11001596B2 (cg-RX-API-DMAC7.html)
EP (2) EP3763717B1 (cg-RX-API-DMAC7.html)
JP (1) JP6793836B2 (cg-RX-API-DMAC7.html)
KR (1) KR102276022B1 (cg-RX-API-DMAC7.html)
CN (2) CN110072867B (cg-RX-API-DMAC7.html)
AU (2) AU2017378060B2 (cg-RX-API-DMAC7.html)
CA (1) CA3045303C (cg-RX-API-DMAC7.html)
CL (1) CL2019001551A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019005287A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190252A (cg-RX-API-DMAC7.html)
CY (1) CY1123577T1 (cg-RX-API-DMAC7.html)
DK (1) DK3555105T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2019000163A (cg-RX-API-DMAC7.html)
EA (1) EA036112B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP19042682A (cg-RX-API-DMAC7.html)
ES (2) ES2835281T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20201882T1 (cg-RX-API-DMAC7.html)
HU (1) HUE052067T2 (cg-RX-API-DMAC7.html)
IL (1) IL267236B (cg-RX-API-DMAC7.html)
JO (1) JOP20190142B1 (cg-RX-API-DMAC7.html)
LT (1) LT3555105T (cg-RX-API-DMAC7.html)
MA (2) MA47399B1 (cg-RX-API-DMAC7.html)
MD (1) MD3555105T2 (cg-RX-API-DMAC7.html)
MX (1) MX385562B (cg-RX-API-DMAC7.html)
MY (1) MY197313A (cg-RX-API-DMAC7.html)
NZ (1) NZ754115A (cg-RX-API-DMAC7.html)
PE (1) PE20190977A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501328B1 (cg-RX-API-DMAC7.html)
PL (1) PL3555105T3 (cg-RX-API-DMAC7.html)
PT (1) PT3555105T (cg-RX-API-DMAC7.html)
RS (1) RS61108B1 (cg-RX-API-DMAC7.html)
SA (1) SA519401897B1 (cg-RX-API-DMAC7.html)
SI (1) SI3555105T1 (cg-RX-API-DMAC7.html)
TN (1) TN2019000158A1 (cg-RX-API-DMAC7.html)
UA (1) UA123640C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018111707A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201903125B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE062424T2 (hu) 2014-09-19 2023-11-28 Forma Therapeutics Inc Piridin-2(1H)-on kinolinon származékok mint mutáns izocitrát dehidrogenáz inhibitorok
CA2961807A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016044781A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
WO2016044787A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US10407419B2 (en) 2015-04-21 2019-09-10 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
UA125824C2 (uk) 2016-10-24 2022-06-15 Астразенека Аб 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ
JP6793836B2 (ja) * 2016-12-16 2020-12-02 イーライ リリー アンド カンパニー 変異体idh1およびidh2阻害剤としての7−フェニルエチルアミノ−4h−ピリミド[4,5−d][1,3]オキサジン−2−オン化合物
MX2022004474A (es) 2016-12-16 2023-08-15 Janssen Pharmaceutica Nv Inhibidores de moléculas pequeñas de la familia de quinasas jak.
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
CR20190379A (es) 2017-01-30 2019-10-21 Astrazeneca Ab Moduladores del receptor de estrógeno
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
SMT202300073T1 (it) 2018-05-16 2023-05-12 Forma Therapeutics Inc Inibizione di idh-1 mutante
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Jak激酶家族之小分子抑制劑
WO2021089395A1 (en) * 2019-11-08 2021-05-14 Nerviano Medical Sciences S.R.L. Gem-disubstituted heterocyclic compounds and their use as idh inhibitors
MX2022011846A (es) * 2020-03-23 2023-01-04 Lilly Co Eli Metodo para el tratamiento de sujetos resistentes al inhibidor idh1.
AU2021242260B2 (en) * 2020-03-23 2023-12-14 Eli Lilly And Company Combination therapy with a mutant IDH inhibitor
EP4125917B1 (en) * 2020-03-23 2024-04-17 Eli Lilly and Company Combination therapy with a mutant idh inhibitor and a bcl-2 inhibitor
US20210330653A1 (en) 2020-04-24 2021-10-28 Astrazeneca Ab Dosage Regimen for the Treatment of Cancer
PE20221838A1 (es) 2020-04-24 2022-11-29 Astrazeneca Ab Formulaciones farmaceuticas
CN115768775B (zh) * 2020-06-28 2024-10-25 微境生物医药科技(上海)有限公司 Idh突变体抑制剂及其用途
CA3186786A1 (en) * 2020-07-20 2022-01-27 David Michael HYMAN Combination therapy with a mutant idh1 inhibitor, a deoxyadenosine analog, and a platinum agent
US12390451B2 (en) 2021-03-11 2025-08-19 Janssen Pharmaceutica Nv Small molecule inhibitor of the JAK family of kinases
CN113588768B (zh) * 2021-05-18 2022-07-05 国家卫生健康委科学技术研究所 一种以分子图像方式定量组织内内源性代谢物的质谱方法
US20240261294A1 (en) * 2021-06-09 2024-08-08 Eli Lilly And Company Method for treating idh inhibitor-resistant subjects
BR112023024454A2 (pt) * 2021-06-15 2024-02-06 Wigen Biomedicine Tech Shanghai Co Ltd Composto de fórmula geral (1) ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; e; uso do composto ou do isômero
EP4384273A1 (en) 2021-08-13 2024-06-19 Eli Lilly and Company Solid forms of 7-[[(1s)-1-[4-[(1s)-2-cyclopropyl-1-(4-prop-2- enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4h- pyrimido[4,5-d] [1,3]oxazin-2-one
WO2023141087A1 (en) 2022-01-19 2023-07-27 Eli Lilly And Company Combination therapy with a mutant idh inhibitor
US20250049809A1 (en) * 2023-07-31 2025-02-13 Board Of Regents, The University Of Texas System Inhibitors of mutant idh1 and idh2

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013046136A1 (en) 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2016171755A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2017019429A1 (en) 2015-07-27 2017-02-02 Eli Lilly And Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015012822A (es) * 2013-03-14 2016-05-31 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
WO2014147586A1 (en) * 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
GB2552283A (en) * 2015-04-24 2018-01-17 Halliburton Energy Services Inc Methods of fabricating ceramic or intermetallic parts
JP6682043B2 (ja) * 2016-06-06 2020-04-15 イーライ リリー アンド カンパニー 変異体idh1阻害剤
JP6793836B2 (ja) * 2016-12-16 2020-12-02 イーライ リリー アンド カンパニー 変異体idh1およびidh2阻害剤としての7−フェニルエチルアミノ−4h−ピリミド[4,5−d][1,3]オキサジン−2−オン化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013046136A1 (en) 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2016171755A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2017019429A1 (en) 2015-07-27 2017-02-02 Eli Lilly And Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors

Also Published As

Publication number Publication date
WO2018111707A1 (en) 2018-06-21
PH12019501328A1 (en) 2020-02-24
TN2019000158A1 (en) 2020-10-05
PL3555105T3 (pl) 2021-05-17
KR20190077539A (ko) 2019-07-03
JP6793836B2 (ja) 2020-12-02
EA036112B1 (ru) 2020-09-29
HUE052067T2 (hu) 2021-04-28
ECSP19042682A (es) 2019-06-30
IL267236A (en) 2019-08-29
CA3045303C (en) 2022-05-17
HRP20201882T1 (hr) 2021-01-22
US20200079791A1 (en) 2020-03-12
LT3555105T (lt) 2021-01-11
PH12019501328B1 (en) 2023-05-12
BR112019009648A2 (pt) 2019-09-10
UA123640C2 (uk) 2021-05-05
MX385562B (es) 2025-03-18
CN110072867A (zh) 2019-07-30
US11629156B2 (en) 2023-04-18
EA201991161A1 (ru) 2019-11-29
PE20190977A1 (es) 2019-07-09
CA3045303A1 (en) 2018-06-21
DOP2019000163A (es) 2019-07-15
US11649247B2 (en) 2023-05-16
JP2020502157A (ja) 2020-01-23
AU2017378060B2 (en) 2020-09-03
CN115109075A (zh) 2022-09-27
ES2941631T3 (es) 2023-05-24
RS61108B1 (sr) 2020-12-31
CY1123577T1 (el) 2022-03-24
MX2019006830A (es) 2019-08-22
NZ754115A (en) 2021-07-30
ES2835281T3 (es) 2021-06-22
JOP20190142B1 (ar) 2023-03-28
US20210230185A1 (en) 2021-07-29
MA47399A (fr) 2019-10-23
MY197313A (en) 2023-06-13
MA53881A (fr) 2022-04-27
EP3763717A1 (en) 2021-01-13
EP3763717B1 (en) 2023-03-08
PT3555105T (pt) 2020-12-21
DK3555105T3 (da) 2020-11-09
MA47399B1 (fr) 2021-02-26
AU2020260493B2 (en) 2021-09-09
US11001596B2 (en) 2021-05-11
US20210206780A1 (en) 2021-07-08
SI3555105T1 (sl) 2020-12-31
CN115109075B (zh) 2024-09-20
CL2019001551A1 (es) 2019-10-25
MD3555105T2 (ro) 2021-01-31
CO2019005287A2 (es) 2019-05-31
SA519401897B1 (ar) 2022-07-28
AU2017378060A1 (en) 2019-05-30
IL267236B (en) 2020-08-31
JOP20190142A1 (ar) 2019-06-13
CN110072867B (zh) 2022-07-08
EP3555105B1 (en) 2020-10-28
CR20190252A (es) 2019-08-26
AU2020260493A1 (en) 2020-11-26
ZA201903125B (en) 2024-08-28
EP3555105A1 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
US11649247B2 (en) 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors
EP3328866B1 (en) 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors
JP6682043B2 (ja) 変異体idh1阻害剤
HK40008100A (en) 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors
HK40008100B (en) 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors
BR112019009648B1 (pt) Compostos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]oxazin-2-ona como inibidores de idh1 e idh2 mutantes, composição farmacêutica que os compreende e seu uso
HK40003055A (en) Mutant idh1 inhibitors

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20190612

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190612

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210226

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210609

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210706

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210707

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240625

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20250630

Start annual number: 5

End annual number: 5